Edwards Lifesciences Corporation (NYSE:EW) – SunTrust Banks dropped their Q2 2018 earnings per share (EPS) estimates for Edwards Lifesciences Corporation in a research report issued to clients and investors on Tuesday, according to Zacks Investment Research. SunTrust Banks analyst B. Nudell now expects that the medical research company will post earnings per share of $1.06 for the quarter, down from their previous estimate of $1.09. SunTrust Banks currently has a “Buy” rating and a $124.00 price target on the stock. SunTrust Banks also issued estimates for Edwards Lifesciences Corporation’s Q4 2018 earnings at $0.97 EPS.
Other equities analysts have also issued research reports about the stock. BidaskClub lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Bank of America Corporation increased their target price on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 target price (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Jefferies Group LLC increased their target price on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $130.00 price target (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $125.17.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/q2-2018-earnings-forecast-for-edwards-lifesciences-corporation-ew-issued-by-suntrust-banks.html.
Edwards Lifesciences Corporation (NYSE EW) opened at $103.85 on Thursday. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. Edwards Lifesciences Corporation has a twelve month low of $81.12 and a twelve month high of $121.45. The company has a market cap of $21,976.73, a price-to-earnings ratio of 28.77, a PEG ratio of 1.86 and a beta of 0.46.
Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The company had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a return on equity of 27.22% and a net margin of 22.47%. Edwards Lifesciences Corporation’s quarterly revenue was up 11.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.68 EPS.
In related news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total value of $594,395.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Larry L. Wood sold 18,960 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $108.54, for a total transaction of $2,057,918.40. The disclosure for this sale can be found here. Over the last quarter, insiders sold 138,580 shares of company stock valued at $15,039,844. 2.13% of the stock is owned by company insiders.
Large investors have recently added to or reduced their stakes in the business. ETF Managers Group LLC bought a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at about $112,000. Shine Investment Advisory Services Inc. bought a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at about $126,000. Cornerstone Advisors Inc. increased its stake in Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares in the last quarter. Alexandria Capital LLC increased its stake in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC bought a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at about $140,000. Institutional investors and hedge funds own 82.17% of the company’s stock.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.